cystine has been researched along with 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorr, RT; Hersh, E; Kepler, CY; Meyers, RO; Pourpak, A; Raymond, MA; Samulitis, BK; Sherry Chow, HH | 1 |
| Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM | 1 |
1 trial(s) available for cystine and 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
| Article | Year |
|---|---|
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Cystine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Half-Life; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfhydryl Compounds; Tomography, X-Ray Computed | 2010 |
1 other study(ies) available for cystine and 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
| Article | Year |
|---|---|
Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cystine; Dose-Response Relationship, Drug; Erythrocytes; Female; Glutathione; Hexanones; Humans; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Xenograft Model Antitumor Assays | 2006 |